Special Investigation of J Zoloft for Panic Disorder Patients
Information source: Pfizer
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Panic Disorder
Intervention: sertraline hydrochloride (Drug)
Phase: Phase 4
Status: Enrolling by invitation
Sponsored by: Pfizer Official(s) and/or principal investigator(s):
Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer
Summary
The objective of this surveillance is to collect information for panic disorder patients
about 1) adverse drug reactions not expected from the LPD (unknown adverse drug reactions),
2) the incidence of adverse drug reactions in this surveillance, and 3) factors considered to
affect the safety and/or efficacy of this drug.
Clinical Details
Official title: Special Investigation of J Zoloft for Panic Disorder Patients
Study design: Case-Only, Prospective
Primary outcome: Factors considered to affect the safety and/or efficacy of this drug.The incidence of adverse drug reactions. The number of adverse drug reactions not expected from the LPD (unknown adverse drug reactions).
Secondary outcome: This study is a non-interventional/observational study and does not have any secondary outcomes measures.
Detailed description:
All the patients of panic disorder whom an investigator prescribes the first Sertraline
hydrochloride should be registered consecutively until the number of subjects reaches target
number in order to extract patients enrolled into the investigation at random.
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients of panic disorder need to be taking Sertraline hydrochloride in order to be
enrolled in the surveillance.
Exclusion Criteria:
- Patients not taking sertraline hydrochloride.
Locations and Contacts
Additional Information
To obtain contact information for a study center near you, click here.
Starting date: April 2007
Ending date: November 2010
Last updated: February 4, 2008
|
